Clinical trials located in


Wesel city is located in Germany. Currently, 7 clinical trials are being conducted in this city.

Wesel, located on the Rhine River in Germany, is a city rich in history and culture. Founded in 1241, it was heavily bombed during World War II, leading to extensive post-war reconstruction. The Willibrordi-Dom, a stunning example of late Gothic architecture, stands as a testament to the city’s resilience. Wesel is also known for its iconic Berliner Tor, a remnant of medieval fortifications. The city played a significant role in the Hanseatic League, showcasing its historical importance in trade and commerce.

  • CT-EU-00057161

    Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Study of the safety and effectiveness of benralizumab in the treatment of asthma in children

    This study examines benralizumab, a potential asthma treatment for children aged 6-18 with severe eosinophilic asthma. Participants, receiving high-dose inhaled corticosteroids and additional medication, are randomly assigned to receive either benralizumab or a placebo without knowing which. The goal is to assess the drug’s effectiveness in reducing asthma exacerbations and improving overall asthma control. Following the initial phase, all participants will receive benralizumab in an open-label extension, monitoring safety and response.

    • Benralizumab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Study of a new drug in children with shortness of breath and wheezing

    This study focuses on Broncho-Vaxom (OM-85), a medication intended to assist children who frequently experience chest infections and encounter difficulties such as wheezing or shortness of breath. The trial is set up to compare three groups of kids from 6 months to 5 years old. The first group will get Broncho-Vaxom (OM-85) for a whole year, the second group will get OM-85 for three months and then a placebo for nine months, and the third will only get the placebo for a year. Observations will be conducted on the children for a year and a half to assess whether there is a reduction in chest infections while they are taking the medication.

    • Broncho-Vaxom/Bacterial Lysates/OM-85
  • Exploring the impact of SanaCutan Basiscreme in delaying atopic dermatitis in high-risk children.

    The trial focuses on evaluating a preventive approach for atopic dermatitis, a common skin disease, in high-risk newborns. These selected infants are at an increased risk due to familial history. The trial involves the application of SanaCutan Basiscreme – a moisturizing cream already approved for treating various skin ailments – on their skin twice daily until they reach 6 months old, with some continuing this treatment until the end of their first year. In parallel, a control group is instructed to avoid the use of skincare products. Any skin issues that appear in either group will be documented and medical examination will be performed regularly. The ultimate goal is to observe if the application of the cream can delay the onset of atopic dermatitis symptoms in these children beyond the first 6 or 12 months of their life.

    • SanaCutan Basiscreme

See more clinical trials in other cities in Germany: